Silberring Jerzy, Ciborowski Pawel
Department of Biochemistry and Neurobiology, Faculty of Materials Science and Ceramics, AGH University of Science and Technology, Kraków, Poland.
Trends Analyt Chem. 2010 Feb 1;29(2):128. doi: 10.1016/j.trac.2009.11.007.
New biomarkers are urgently needed to accelerate efforts in developing new drugs and treatments of known diseases. New clinical and translational proteomics studies emerge almost every day. However, discovery of new diagnostic biomarkers lags behind because of variability at every step in proteomics studies (e.g., assembly of a cohort of patients, sample preparation and the nature of body fluids, selection of a profiling method and uniform protocols for data analysis).Quite often, the validation step that follows the discovery phase does not reach desired levels of sensitivity and specificity or reproducibility between laboratories. Mass spectrometry and gel-based methods do not provide enough throughput for screening thousands of clinical samples. Further development of protein arrays may address this issue.Despite many obstacles, proteomics delivers vast amounts of information useful for understanding the molecular mechanisms underlying diseases.
迫切需要新的生物标志物来加速已知疾病新药和治疗方法的研发进程。几乎每天都有新的临床和转化蛋白质组学研究出现。然而，由于蛋白质组学研究的每一步都存在变异性（例如，患者队列的组建、样本制备以及体液的性质、分析方法的选择和统一的数据分析方案），新诊断生物标志物的发现滞后。通常，在发现阶段之后的验证步骤无法达到实验室间所需的灵敏度、特异性或可重复性水平。质谱法和基于凝胶的方法无法提供足够的通量来筛选数千份临床样本。蛋白质阵列的进一步发展可能会解决这一问题。尽管存在许多障碍，但蛋白质组学提供了大量有助于理解疾病潜在分子机制的信息。
